Stock Update (NYSE:MRK): Merck’s 9-Valent HPV Vaccine, GARDASIL®9, Recommended by CDC’s Advisory Committee on Immunization Practices for Females Aged 9-26 and Males Aged 9-21

[Business Wire] – Merck , known as MSD outside the United States and Canada, announced today that the U.S. Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to include . . . → Read More: Stock Update (NYSE:MRK): Merck’s 9-Valent HPV Vaccine, GARDASIL®9, Recommended by CDC’s Advisory Committee on Immunization Practices for Females Aged 9-26 and Males Aged 9-21 Similar Articles: Market Update (NYSE:MRK): Merck Announces Second-Quarter 2015 Dividend Market Update: Merck & Co Inc (NYSE:MRK) – Merck’s Insomnia Medicine BELSOMRA® (suvorexant) C-IV, the First and Only Orexin Receptor Antagonist, Now Available in the United States Stock Update: Merck & Co Inc (NYSE:MRK) – Merck Completes Tender Offer to Acquire Cubist
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.